5-羟甲基-1-甲基-2-甲硫基-1H-咪唑 | 107718-01-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-羟甲基-1-甲基-2-甲硫基-1H-咪唑
• 英文名称: [1-methyl-2-(methylsulphanyl)-1H-imidazol-5-yl]methanol
• 英文别名: (1-methyl-2-(methylthio)-1H-imidazol-5-yl)methanol；1-methyl-2-methylthio-5-hydroxymethyl-1H-imidazole；5-hydroxymethyl-2-methylthio-1-methylimidazole；1H-1-methyl-2-(methylthio)imidazol-5yl-methanol；[1-methyl-2-(methylsulfanyl)-1H-imidazol-5-yl]methanol；(3-methyl-2-methylsulfanylimidazol-4-yl)methanol
• CAS: 107718-01-4
• 化学式: C₆H₁₀N₂OS
• 分子量: 158.224
• InChiKey: JSGNXGJXVXAVGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-羟甲基-1-甲基-2-甲硫基-1H-咪唑 在 manganese(IV) oxide 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 24.0h， 生成 10-(1-methyl-2-(methylthio)-1H-imidazol-5-yl)-5-phenyl-7,8-dihydro-5H-indeno[1,2-b]quinoline-9,11(6H,10H)-dione
  参考文献：
  名称：

  Synthesis and antiproliferative activity evaluation of imidazole-based indeno[1,2-b]quinoline-9,11-dione derivatives

  摘要：

  一系列新的咪唑取代的印烯[1,2-b]喹啉-9,11-二酮衍生物被合成并评估了其对人类癌细胞系HeLa、LS180、MCF-7和Jurkat的抗增殖效果。抗增殖效果通过MTT法进行评估。所制备的化合物在评估的细胞系中表现出从弱到良好的抗增殖活性。在与LS180、HeLa和MCF-7细胞系相比时，所制备的化合物在Jurkat细胞系中的效能更强。化合物29（IC16 = 0.7 μM）、31（IC16 = 1.7 μM）和33（IC16 = 1.7 μM）被发现是Jurkat细胞系中最有效的分子。此外，发现一些在双氢吡啶环C11位点上带有咪唑-2-基的测试化合物，其抗增殖活性优于顺铂，特别是在Jurkat细胞系中（化合物29、31和33）。似乎在咪唑环上引入电子吸引基团增强了这些化合物的抗增殖潜力（化合物27、29和31）。本研究结果表明，一些咪唑取代的印烯[1,2-b]喹啉-9,11-二酮化合物可能作为有效的抗癌剂在体外发挥作用，强调了它们作为有效抗增殖剂的合理设计来源的潜在角色。

  DOI：

  10.1007/s12272-013-0032-7
• 作为产物：
  描述：

  methyl 1-methyl-2-(methylsulphanyl)-1H-imidazole-5-carbpxylate 在 三乙基硼氢化锂 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以94%的产率得到5-羟甲基-1-甲基-2-甲硫基-1H-咪唑
  参考文献：
  名称：

  Design, Synthesis and Evaluation of Imidazolylmethyl Carbamate Prodrugs of Alkylating Agents

  摘要：

  Two approaches to prodrugs of alkylating agents based on an imidazolylmethyl carbamate nucleus were explored. A 2-azido analogue (3) of the bis-carbamate carmethizole (1) displayed similar aerobic cytotoxicity to 1 in a panel of human and murine cell lines. Approaches to the 2-amino and 2-carbamoyl analogues are described. In the second approach an imidazolylmethanol was used as a 'trigger' linked via a carbamate to the alkylating agent N,N-bis(2-chlorethyl)amine (BCEA). Nitroimidazole and methylsulphinylimidazole carbamate prodrugs 6-8 were 5-20-fold less toxic than BCEA. Despite this deactivation in the prodrug form, little increase in cytotoxicity was observed under hypoxia. The data suggest that BCEA released on bioreduction is not sufficiently potent to contribute significant additional cytotoxicity. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)01031-5

文献信息

• Azaindoles
  申请人：——

  公开号：US20040009983A1

  公开（公告）日：2004-01-15

  The invention is directed to compositions containing physiologically active compounds of general formula (I): 1 wherein R 1 is aryl or heteroaryl; R 2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, —Z 1 R 8 , —C(═O)—NY 3 Y 4 , —CO 2 R 8 , —NY 3 Y 4 , —N(R 6 )—C(═O)—R 7 , —N(R 6 )—C(═O)—NY 3 Y 4 , —N(R 6 )—C(═O)—OR 7 , —N(R 6 )—SO 2 —R 7 , —N(R 6 )—SO 2 —NY 3 Y 4 and one or more halogen a toms ; R 3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, —C(═O)—OR 5 or —C(═O)—NY 3 Y; and X 1 represents N, CH, C-halo, C—CN, C—R 7 , C—NY 3 Y 4 , C—OH, C—Z 2 R 7 , C—C(═O)—OR 5 , C—C(═O)—NY 3 Y 4 , C—N(R 8 )—C(═O)—R 7 , C—SO 2 —NY 3 Y 4 , C—N(R 8 )—SO 2 —R 7 , C-alkenyl, C-alkynyl or C—NO 2 ; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.

  这项发明涉及含有一般式（I）中生理活性化合物的组合物：其中R1为芳基或杂芳基；R2代表氢、酰基、氰基、卤素、可选择地由氰基、杂芳基、杂环烷基、—Z1R8、—C（═O）—NY3Y4、—CO2R8、—NY3Y4、—N(R6)—C（═O）—R7、—N(R6)—C（═O）—NY3Y4、—N(R6)—C（═O）—OR7、—N(R6)—SO2—R7、—N(R6)—SO2—NY3Y4和一个或多个卤原子取代的较低烯基或较低烷基；R3代表氢、芳基、氰基、卤素、杂芳基、较低烷基、—C（═O）—OR5或—C（═O）—NY3Y；X1代表N、CH、C-卤素、C—CN、C—R7、C—NY3Y4、C—OH、C—Z2R7、C—C（═O）—OR5、C—C（═O）—NY3Y4、C—N(R8)—C（═O）—R7、C—SO2—NY3Y4、C—N(R8)—SO2—R7、C-烯基、C-炔基或C—NO2；以及它们的前药、这些化合物及其前药的药学上可接受的盐和溶剂，以及在一般式（I）范围内的新化合物。这些化合物和组合物具有有价值的药物特性，特别是抑制蛋白激酶的能力。
• 4,5-Disubstituted <i>N</i> -Methylimidazoles as Versatile Building Blocks for Defined Side-Chain Introduction
  作者：Daniel Przybyla、Udo Nubbemeyer

  DOI：10.1002/ejoc.201601384

  日期：2017.1.18

  Two strategies for the synthesis of fungerin and its derivatives have been developed. An orthogonally protected key 4,5‐di(hydroxymethyl)imidazole intermediate gave fungerin analogues in five steps. Furthermore 5‐(2‐sulfonylethyl)‐4‐bromoimidazole gave several target imidazoles after two additional steps with complete regioselectivity.

  已经开发了两种合成真菌素及其衍生物的策略。正交保护的关键4,5-二（羟甲基）咪唑中间体通过五个步骤提供了fungerin类似物。此外，在另外两个步骤后，5-（2-磺酰基乙基）-4-溴咪唑具有完全的区域选择性，从而生成了几种目标咪唑。
• Synthesis of aryl ω-(1-methyl-5-imidazolyl and 1<i>H</i>-5-tetrazolyl)alkyl ketones
  作者：Jae Jeong Lee、Liang-Fu Huang、Kyaw Zaw、Ludwig Bauer

  DOI：10.1002/jhet.5570350116

  日期：1998.1

  Successful syntheses of 2,4-dichlorophenyl 2-(1-methyl-5-imidazolyl)ethyl and 2,4-dichlorophenyl 3-(1-methyl-5-imidazolyl)propyl ketones are described. In addition, syntheses of 2,4-dichlorophenyl and 4-chlorophenyl 3-(1-methyl-1H-5-tetrazolyl)propyl ketones are reported.

  描述了成功合成2,4-二氯苯基2-（1-甲基-5-咪唑基）乙基和2,4-二氯苯基3-（1-甲基-5-咪唑基）丙基酮。另外，据报道合成了2，4-二氯苯基和4-氯苯基3-（1-甲基-1 H -5-四唑基）丙基酮。
• Syntheses of substituted pyrrolo[2,3-<i>d</i>]imidazoles
  作者：A. Shafiee、F. Hadizadeh

  DOI：10.1002/jhet.5570340233

  日期：1997.3

  Starting from the readily available 5-hydroxymethyl-2-mercapto-1-methylimidazole (1) substituted pyrrolo[2,3-d]imidazoles were prepared.

  从容易获得的5-羟甲基-2-巯基-1-甲基咪唑（1）开始，制备取代的吡咯并[2，3- d ]咪唑。
• Design, synthesis and biological evaluation of novel imidazole-based benzamide and hydroxamic acid derivatives as potent histone deacetylase inhibitors and anticancer agents
  作者：Mahda Sadat Nasrollahzadeh、Vahid Eskandarpour、Mahdi Faal Maleki、Farhad Eisvand、Mohammad Mashreghi、Farzin Hadizadeh、Zahra Tayarani-Najaran、Razieh Ghodsi

  DOI：10.1016/j.molstruc.2023.136951

  日期：2024.2

  New imidazoles bearing benzamide or hydroxamic acid group (as Zn binding groups) were designed and synthesized as HDAC inhibitors. Cytotoxicity of the compounds was evaluated against three types of cancer cells including HCT-116, A549, PC3 and a normal cell line (CHO). The inhibitory activities of the compounds were investigated against pan-HDAC isozymes including HDACs 1, 2, 3 and 6 and the activity

  设计并合成了带有苯甲酰胺或异羟肟酸基团（作为锌结合基团）的新型咪唑作为 HDAC 抑制剂。针对三种类型的癌细胞（包括 HCT-116、A549、PC3 和正常细胞系 (CHO)）评估了化合物的细胞毒性。研究了这些化合物对泛 HDAC 同工酶（包括 HDAC 1、2、3 和 6）的抑制活性，并评估了最有效的泛 HDAC 抑制剂对 HDAC1 的活性。大多数化合物对癌细胞表现出显着的细胞毒性，但对正常 CHO 细胞系没有表现出显着的细胞毒性。化合物7d对所有测试的癌细胞都显示出有希望的抗增殖活性，比其他化合物更强。该化合物对 HCT-116 细胞系表现出显着的细胞毒性。化合物7c、6a、7b在 HCT-116 细胞系中显示出强的泛 HDAC 抑制活性，几乎与恩替司他相同。化合物7d和7c强烈抑制HDAC1，IC 50值分别为0.56 μM和0.77 μM，与Entinostat (IC 50 =

表征谱图